911.7500 0.95 (0.10%)
NSE Dec 16, 2025 15:31 PM
Volume: 66,682
 

911.75
0.10%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Number of FII/FPI investors decreased from 101 to 92 in Sep 2025 qtr
More from Alivus Life Sciences Ltd.
Recommended